Biophytis Initiates Phase 2 Clinical Study for Obesity Treatment with BIO101

Biophytis SA, a biotechnology firm focused on developing therapies for age-related diseases, has announced the commencement of the OBA phase 2 clinical study targeting obesity. The study will investigate the efficacy of BIO101 combined with GLP-1 receptor agonists. This development follows promising preclinical outcomes that suggest BIO101's potential in mitigating muscle mass loss commonly associated with obesity treatments.

Obesity treatments, especially those involving GLP-1 receptor agonists, often lead to significant muscle loss, posing a challenge given the crucial role of muscle in metabolism and motor functions. With over 15 million US adults projected to use anti-obesity medication by 2030, the demand for solutions preserving muscle function is increasing. This backdrop frames the significance of the OBA study, expected to begin mid-2024 with results anticipated in 2025.

BIO101 has shown positive metabolic effects on muscle and fat tissues in earlier studies, raising hopes for its effectiveness in obesity treatment. It aims to improve mobility and muscle strength in obese patients experiencing muscle wastage due to severe weight loss measures. The upcoming study marks a strategic move by Biophytis to address a growing market challenge, capitalizing on the untapped potential in obesity management. Detailed information about the OBA program and the clinical study will be provided in the upcoming weeks.